Viking Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update




VK5211 Phase 2 hip fracture study nearing completion, data expected 4Q17



VK2809 Phase 2 fatty liver and hypercholesterolemia study proceeding



Final VK2809 data from in vivo NASH model demonstrates significant improvements in fibrosis, steatosis and NAFLD activity score



Positive data presentations support continued development of orphan drug programs in GSD Ia and X-ALD



Conference call scheduled for 4:30 pm ET today



SAN DIEGO, November 8, 2017 -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the third quarter ended September 30, 2017, and provided an update on its clinical pipeline and other corporate developments.


Highlights from, and Subsequent to, the Quarter Ended September 30, 2017


“The last few months have been an exciting time at Viking as we continued moving forward with multiple pipeline programs.  Since our last update we presented positive data from three different programs at scientific conferences, which served to underscore the depth and quality of our pipeline.  Looking ahead, we remain on track to announce by year-end the results from a Phase 2 trial of our novel SARM program VK5211 in patients recovering from hip fracture,” stated Brian Lian, Ph.D., chief executive officer of Viking.  “We are also continuing to enroll patients in the Phase 2 trial of our novel thyroid receptor beta agonist VK2809 in hypercholesterolemia and fatty liver disease, and we expect to complete this study in the first half of 2018.  With respect to our orphan programs, we made progress with both VK2809 in glycogen storage disease and VK0214 in X-ALD and we’re excited by recent results from each program.  On the corporate side, during the quarter we entered into stock purchase agreements for up to $16.25 million with an institutional investor, providing financing flexibility.  We also added to our Board of Directors through the appointment of Charles A. Rowland, Jr., an experienced biopharma finance executive.”  



The following information was filed by Viking Therapeutics, Inc. (VKTX) on Wednesday, November 8, 2017 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Viking Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Viking Therapeutics, Inc..


Never Miss A New SEC Filing Again

Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.


We Highlighted This SEC Filing For You

SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.


Widen Your SEC Filing Reading Experience

Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view


Uncover Actionable Information Inside SEC Filings

SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q


Adobe PDF, Microsoft Word and Excel Downloads

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis


FREE Financial Statements

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator

Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019) Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not


Financial Stability Report

Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019) Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity


Get a Better Picture of a Company's Performance

Financial Ratios
Available Financial Ratios Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years


Log in with your credentials


Forgot your details?

Create Account